Driving vascular endothelial cell fate of human multipotent Isl1 + heart progenitors with VEGF modified mRNA

Kathy O. Lui, Lior Zangi, Eduardo Silva, Lei Bu, Makoto Sahara, Ronald A. Li, David J. Mooney, Kenneth R. Chien

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Distinct families of multipotent heart progenitors play a central role in the generation of diverse cardiac, smooth muscle and endothelial cell lineages during mammalian cardiogenesis. The identification of precise paracrine signals that drive the cell-fate decision of these multipotent progenitors, and the development of novel approaches to deliver these signals in vivo, are critical steps towards unlocking their regenerative therapeutic potential. Herein, we have identified a family of human cardiac endothelial intermediates located in outflow tract of the early human fetal hearts (OFT-ECs), characterized by coexpression of Isl1 and CD144/vWF. By comparing angiocrine factors expressed by the human OFT-ECs and non-cardiac ECs, vascular endothelial growth factor (VEGF)-A was identified as the most abundantly expressed factor, and clonal assays documented its ability to drive endothelial specification of human embryonic stem cell (ESC)-derived Isl1 + progenitors in a VEGF receptor-dependent manner. Human Isl1-ECs (endothelial cells differentiated from hESC-derived ISL1 + progenitors) resemble OFT-ECs in terms of expression of the cardiac endothelial progenitor-and endocardial cell-specific genes, confirming their organ specificity. To determine whether VEGF-A might serve as an in vivo cell-fate switch for human ESC-derived Isl1-ECs, we established a novel approach using chemically modified mRNA as a platform for transient, yet highly efficient expression of paracrine factors in cardiovascular progenitors. Overexpression of VEGF-A promotes not only the endothelial specification but also engraftment, proliferation and survival (reduced apoptosis) of the human Isl1 + progenitors in vivo. The large-scale derivation of cardiac-specific human Isl1-ECs from human pluripotent stem cells, coupled with the ability to drive endothelial specification, engraftment, and survival following transplantation, suggest a novel strategy for vascular regeneration in the heart.

Original languageEnglish (US)
Pages (from-to)1172-1186
Number of pages15
JournalCell Research
Volume23
Issue number10
DOIs
StatePublished - Oct 1 2013

Fingerprint

Vascular Endothelial Growth Factor A
Endothelial Cells
Messenger RNA
Fetal Heart
Pluripotent Stem Cells
Organ Specificity
Vascular Endothelial Growth Factor Receptor
Survival
Cell Lineage
Cardiac Myocytes
Smooth Muscle Myocytes
Blood Vessels
Regeneration
Transplantation
Apoptosis
Genes
Human Embryonic Stem Cells

Keywords

  • cardiovascular progenitors
  • endothelial cells
  • Isl1
  • mRNA
  • VEGF-A

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Biology

Cite this

Driving vascular endothelial cell fate of human multipotent Isl1 + heart progenitors with VEGF modified mRNA. / Lui, Kathy O.; Zangi, Lior; Silva, Eduardo; Bu, Lei; Sahara, Makoto; Li, Ronald A.; Mooney, David J.; Chien, Kenneth R.

In: Cell Research, Vol. 23, No. 10, 01.10.2013, p. 1172-1186.

Research output: Contribution to journalArticle

Lui, KO, Zangi, L, Silva, E, Bu, L, Sahara, M, Li, RA, Mooney, DJ & Chien, KR 2013, 'Driving vascular endothelial cell fate of human multipotent Isl1 + heart progenitors with VEGF modified mRNA', Cell Research, vol. 23, no. 10, pp. 1172-1186. https://doi.org/10.1038/cr.2013.112
Lui, Kathy O. ; Zangi, Lior ; Silva, Eduardo ; Bu, Lei ; Sahara, Makoto ; Li, Ronald A. ; Mooney, David J. ; Chien, Kenneth R. / Driving vascular endothelial cell fate of human multipotent Isl1 + heart progenitors with VEGF modified mRNA. In: Cell Research. 2013 ; Vol. 23, No. 10. pp. 1172-1186.
@article{367220646323421086dcc3a0fc1e069d,
title = "Driving vascular endothelial cell fate of human multipotent Isl1 + heart progenitors with VEGF modified mRNA",
abstract = "Distinct families of multipotent heart progenitors play a central role in the generation of diverse cardiac, smooth muscle and endothelial cell lineages during mammalian cardiogenesis. The identification of precise paracrine signals that drive the cell-fate decision of these multipotent progenitors, and the development of novel approaches to deliver these signals in vivo, are critical steps towards unlocking their regenerative therapeutic potential. Herein, we have identified a family of human cardiac endothelial intermediates located in outflow tract of the early human fetal hearts (OFT-ECs), characterized by coexpression of Isl1 and CD144/vWF. By comparing angiocrine factors expressed by the human OFT-ECs and non-cardiac ECs, vascular endothelial growth factor (VEGF)-A was identified as the most abundantly expressed factor, and clonal assays documented its ability to drive endothelial specification of human embryonic stem cell (ESC)-derived Isl1 + progenitors in a VEGF receptor-dependent manner. Human Isl1-ECs (endothelial cells differentiated from hESC-derived ISL1 + progenitors) resemble OFT-ECs in terms of expression of the cardiac endothelial progenitor-and endocardial cell-specific genes, confirming their organ specificity. To determine whether VEGF-A might serve as an in vivo cell-fate switch for human ESC-derived Isl1-ECs, we established a novel approach using chemically modified mRNA as a platform for transient, yet highly efficient expression of paracrine factors in cardiovascular progenitors. Overexpression of VEGF-A promotes not only the endothelial specification but also engraftment, proliferation and survival (reduced apoptosis) of the human Isl1 + progenitors in vivo. The large-scale derivation of cardiac-specific human Isl1-ECs from human pluripotent stem cells, coupled with the ability to drive endothelial specification, engraftment, and survival following transplantation, suggest a novel strategy for vascular regeneration in the heart.",
keywords = "cardiovascular progenitors, endothelial cells, Isl1, mRNA, VEGF-A",
author = "Lui, {Kathy O.} and Lior Zangi and Eduardo Silva and Lei Bu and Makoto Sahara and Li, {Ronald A.} and Mooney, {David J.} and Chien, {Kenneth R.}",
year = "2013",
month = "10",
day = "1",
doi = "10.1038/cr.2013.112",
language = "English (US)",
volume = "23",
pages = "1172--1186",
journal = "Cell Research",
issn = "1001-0602",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Driving vascular endothelial cell fate of human multipotent Isl1 + heart progenitors with VEGF modified mRNA

AU - Lui, Kathy O.

AU - Zangi, Lior

AU - Silva, Eduardo

AU - Bu, Lei

AU - Sahara, Makoto

AU - Li, Ronald A.

AU - Mooney, David J.

AU - Chien, Kenneth R.

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Distinct families of multipotent heart progenitors play a central role in the generation of diverse cardiac, smooth muscle and endothelial cell lineages during mammalian cardiogenesis. The identification of precise paracrine signals that drive the cell-fate decision of these multipotent progenitors, and the development of novel approaches to deliver these signals in vivo, are critical steps towards unlocking their regenerative therapeutic potential. Herein, we have identified a family of human cardiac endothelial intermediates located in outflow tract of the early human fetal hearts (OFT-ECs), characterized by coexpression of Isl1 and CD144/vWF. By comparing angiocrine factors expressed by the human OFT-ECs and non-cardiac ECs, vascular endothelial growth factor (VEGF)-A was identified as the most abundantly expressed factor, and clonal assays documented its ability to drive endothelial specification of human embryonic stem cell (ESC)-derived Isl1 + progenitors in a VEGF receptor-dependent manner. Human Isl1-ECs (endothelial cells differentiated from hESC-derived ISL1 + progenitors) resemble OFT-ECs in terms of expression of the cardiac endothelial progenitor-and endocardial cell-specific genes, confirming their organ specificity. To determine whether VEGF-A might serve as an in vivo cell-fate switch for human ESC-derived Isl1-ECs, we established a novel approach using chemically modified mRNA as a platform for transient, yet highly efficient expression of paracrine factors in cardiovascular progenitors. Overexpression of VEGF-A promotes not only the endothelial specification but also engraftment, proliferation and survival (reduced apoptosis) of the human Isl1 + progenitors in vivo. The large-scale derivation of cardiac-specific human Isl1-ECs from human pluripotent stem cells, coupled with the ability to drive endothelial specification, engraftment, and survival following transplantation, suggest a novel strategy for vascular regeneration in the heart.

AB - Distinct families of multipotent heart progenitors play a central role in the generation of diverse cardiac, smooth muscle and endothelial cell lineages during mammalian cardiogenesis. The identification of precise paracrine signals that drive the cell-fate decision of these multipotent progenitors, and the development of novel approaches to deliver these signals in vivo, are critical steps towards unlocking their regenerative therapeutic potential. Herein, we have identified a family of human cardiac endothelial intermediates located in outflow tract of the early human fetal hearts (OFT-ECs), characterized by coexpression of Isl1 and CD144/vWF. By comparing angiocrine factors expressed by the human OFT-ECs and non-cardiac ECs, vascular endothelial growth factor (VEGF)-A was identified as the most abundantly expressed factor, and clonal assays documented its ability to drive endothelial specification of human embryonic stem cell (ESC)-derived Isl1 + progenitors in a VEGF receptor-dependent manner. Human Isl1-ECs (endothelial cells differentiated from hESC-derived ISL1 + progenitors) resemble OFT-ECs in terms of expression of the cardiac endothelial progenitor-and endocardial cell-specific genes, confirming their organ specificity. To determine whether VEGF-A might serve as an in vivo cell-fate switch for human ESC-derived Isl1-ECs, we established a novel approach using chemically modified mRNA as a platform for transient, yet highly efficient expression of paracrine factors in cardiovascular progenitors. Overexpression of VEGF-A promotes not only the endothelial specification but also engraftment, proliferation and survival (reduced apoptosis) of the human Isl1 + progenitors in vivo. The large-scale derivation of cardiac-specific human Isl1-ECs from human pluripotent stem cells, coupled with the ability to drive endothelial specification, engraftment, and survival following transplantation, suggest a novel strategy for vascular regeneration in the heart.

KW - cardiovascular progenitors

KW - endothelial cells

KW - Isl1

KW - mRNA

KW - VEGF-A

UR - http://www.scopus.com/inward/record.url?scp=84885172335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885172335&partnerID=8YFLogxK

U2 - 10.1038/cr.2013.112

DO - 10.1038/cr.2013.112

M3 - Article

C2 - 24018375

AN - SCOPUS:84885172335

VL - 23

SP - 1172

EP - 1186

JO - Cell Research

JF - Cell Research

SN - 1001-0602

IS - 10

ER -